Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach.
Fiche publication
Date publication
octobre 2022
Journal
International journal of molecular sciences
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PAUL Catherine, Pr DENAT Franck, Dr COLLIN Bertrand, Dr ASGAROV Kamal, Dr BELLAYE Pierre-Simon
Tous les auteurs :
Baurand PE, Balland J, Reynas C, Ramseyer M, Vivier D, Bellaye PS, Collin B, Paul C, Denat F, Asgarov K, Pallandre JR, Ringenbach L
Lien Pubmed
Résumé
The human leucine-rich repeat-containing protein 15 (LRRC15) is a membrane protein identified as a marker of CAF (cancer-associated fibroblast) cells whose overexpression is positively correlated with cancer grade and outcome. Nuclear molecular imaging (i.e., SPECT and PET) to track LRRC15 expression could be very useful in guiding further therapeutic strategies. In this study, we developed an ScFv mouse phage-display library to obtain small fragment antibodies against human LRRC15 for molecular imaging purposes. Mice were immunized with recombinant human LRRC15 (hLRRC15), and lymph node cells were harvested for ScFv (single-chain variable fragment) phage-display analysis. The built library was used for panning on cell lines with constitutive or induced expression after transfection. The choice of best candidates was performed by screening various other cell lines, using flow cytometry. The selected candidates were reformatted into Cys-ScFv or Cys-diabody by addition of cysteine, and cloned in mammalian expression vectors to obtain batches of small fragments that were further used in site-specific radiolabeling tests. The obtained library was 1.2 × 10 cfu/µg with an insertion rate >95%. The two panning rounds performed on cells permittedenrichment of 2 × 10. Screening with flow cytometry allowed us to identify 28 specific hLRRC15 candidates. Among these, two also recognized murine LRCC15 and were reformatted into Cys-ScFv and Cys-diabody. They were expressed transiently in a mammalian system to obtain 1.0 to 4.5 mg of Cys fragments ready for bioconjugation and radiolabeling. Thus, in this paper, we demonstrate the relevance of the phage-display ScFv library approach for the fast-track development of small antibodies for imaging and/or immunotherapy purposes.
Mots clés
Cys-ScFv, Cys-diabodies, LRRC15, ScFv immune libraries, imaging agents, immunotherapy, phage display, small antibody fragments
Référence
Int J Mol Sci. 2022 10 21;23(20):